Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ResisCHIP

Financiado

Rapid chip-based detection of antibiotic resistances

Drug-resistant infections are one of the greatest threats facing humanity. Antimicrobial resistance (AMR) causes over 700.000 deaths each year. Furthermore, AMR is associated to reduced quality of life, increased hospitalization p... ver más

30/11/2023

UAB

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAT AUTÒNOMA DE BARCELONA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 1264

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1

I+D

Cerrada hace 3 años

0% 100% 100%

2 Participantes

UAB

115.00K€ | Lider

DAY ONE

35.00K€ | Participante

Proyectos interesantes

DRAIGON Diagnosing Infections with Multi-Drug Resistant Microorganis... 7M€ Cerrado

COMBACTE-NET Combatting Bacterial Resistance in Europe 221M€ Cerrado

GREAT-LIFE Linking Infectious disease Front-liners’ control Efforts wit... 5M€ Cerrado

OUTSMART-infection Microbiome centered prediction and prevention of recurrent i... 3M€ Cerrado

PLEC2021-007972 Amplificación de la polimerasa en combinación con un array e... 200K€ Cerrado

GEM-SEE-Achro GEM-SEE-Achro: Genomic Exploration—Mapping the Spread, Evolu... 159K€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2022-05-17
Fecha Fin: 2023-11-30

Líder del proyecto

UNIVERSITAT AUTÒNOMA DE BARCELONA

Total investigadores 1264

Presupuesto del proyecto 150K€

Descripción del proyecto Drug-resistant infections are one of the greatest threats facing humanity. Antimicrobial resistance (AMR) causes over 700.000 deaths each year. Furthermore, AMR is associated to reduced quality of life, increased hospitalization periods and medical costs. Misuse and over-prescription of antibiotics for human or animal treatment are one of the drivers of AMR. At the same time, the development of new antibiotics is virtually nonexistent. Hence, developing fast diagnostic methods to identify the optimal treatment is key to effectively fight AMR and increase survival rates of patients encountering life-threatening infections. So far, diagnostics rely on bacterial cultures, leading to slow turnaround times, which are linked to the preventive administration of broad-spectrum antibiotics, often inefficient and leading to worse disease outcomes and spread of AMR. Novel approaches such as DNA PCR-based diagnostic panels or next generation sequencing methods have been recently proposed to address this issue. However, they are target a limited number of pathogens and genes or require expensive equipment and highly-trained personnel. Furthermore, they require a culture step to reach detection levels, usually lasting a few hours, that can be critical for serious conditions. Recently, using technology derived from ERC StG and PoC grants, we designed a method to concentrate, purify, and isolate bacterial RNA in just 5 minutes. Here, we seek to develop and validate these tools, combined with a rapid RNA chip array with single-molecule resolution, to provide a culture-free, fast, and highly sensitive alternative to bacterial infection diagnostics from direct blood samples. Once developed, ResisCHIP will provide a tailor-made diagnostic kit with the capacity to identify thousands of genes and pathogens from a blood sample in less than 2 hours, allowing the rapid selection of the best treatment, improving AMR stewardess, and becoming a significant breakthrough in AMR diagnostics.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores